insights_auto
为什么 RARE 上涨了 3.19%?
深入探索chevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$15.22
arrow_upward
+3.19%(+0.47) 1 天
US$15.05
arrow_downward
-1.12% (-0.17)bedtime盘后交易
休市： 10月2日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 RARE 生成关键数据洞见…
开盘价
US$14.90
最高价
US$15.28
最低价
US$14.67
市值
15.01亿
平均成交量
572.40万
成交量
388.08万
52 周最高价
US$39.89
52 周最低价
US$12.73
每股收益
-US$5.84
Beta 版
0.35
流通股数
9858.90万
员工人数
1371
开盘价
US$14.90
最高价
US$15.28
最低价
US$14.67
市值
15.01亿
平均成交量
572.40万
成交量
388.08万
52 周最高价
US$39.89
52 周最低价
US$12.73
每股收益
-US$5.84
Beta 版
0.35
流通股数
9858.90万
员工人数
1371
新闻报道
来自网络来源和新闻合作伙伴
资料
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc简介